NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Debt
Debt-to-Equity Ratio0.77
Current Ratio2.41
Quick Ratio1.30
Price-To-Earnings
Trailing P/E Ratio28.17
Forward P/E Ratio21.35
P/E Growth1.61
Sales & Book Value
Annual Sales$1.03 billion
Price / Sales2.60
Cash Flow$4.6088 per share
Price / Cash11.35
Book Value$15.68 per share
Price / Book3.34
Profitability
EPS (Most Recent Fiscal Year)$1.91
Net Income$83 million
Net Margins4.14%
Return on Equity13.14%
Return on Assets6.11%
Miscellaneous
Employees2,600
Outstanding Shares51,260,000
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive declared that its board has authorized a stock buyback program on Wednesday, October 25th 2017, which allows the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Tuesday, May, 1st. The medical device company reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.06. The medical device company earned $260.50 million during the quarter, compared to the consensus estimate of $259.43 million. NuVasive had a net margin of 4.14% and a return on equity of 13.14%. The company's quarterly revenue was up 4.6% on a year-over-year basis. During the same period last year, the firm posted $0.37 earnings per share. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $2.44-2.47 for the period, compared to the Thomson Reuters consensus estimate of $2.46. The company issued revenue guidance of $1.095-1.105 billion, compared to the consensus revenue estimate of $1.10 billion.
What price target have analysts set for NUVA?
17 Wall Street analysts have issued twelve-month price objectives for NuVasive's stock. Their forecasts range from $47.00 to $90.00. On average, they anticipate NuVasive's share price to reach $65.50 in the next year. View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. Needham & Company LLC analysts commented, "NUVA’s 1Q18 revenue beat and EPS missed consensus. Management reiterated its 2018 revenue and EPS guidance. Organic revenue growth improved to 2% in 1Q18 from 0% in 4Q17 as US Spinal Hardware and biologics growth improved. NUVA’s revenue guidance requires it to accelerate its revenue growth; we believe that it can do this given new products, easing comps, and stabilization of biologics. And its EPS guidance requires a substantial improvement in its gross and operating margin; we believe it can do this with improvements in its new manufacturing plant and SG&A leverage. Unfortunately, both the revenue and margin ramps are likely to continue to make NUVA a show me" story despite its discount P/E multiple." (5/2/2018)
- 2. According to Zacks Investment Research, "NuVasive has underperformed its industry over the past six months. The company's U.S. business has been delivering dull performance with softness in both U.S. Spinal Hardware and U.S. Surgical Support businesses. However, solid performance of the international business with more than 20% growth for the fifth consecutive quarter buoys optimism. The company’s expectation to higher adjusted operating profit margin of at least 100 bps in 2018 reflects its focus on operational efficiencies and in-house manufacturing facility. Moreover, we are upbeat about the recently-completed buyout of SafePassage. Per NuVasive, the acquisition will strengthen the company's intraoperative neuromonitoring business line. The consolidated giant is expected to deliver services to more than 1,000 customers and 3,000 surgeons." (5/1/2018)
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS) and Luminex (LMNX).
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
- Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
- Mr. Jason Marshall Hannon, Former Pres & COO (Age 46)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
- Mr. Jereme Sylvain, Chief Accounting Officer (Age 38)
Has NuVasive been receiving favorable news coverage?
Media stories about NUVA stock have trended somewhat positive this week, Accern reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuVasive earned a media sentiment score of 0.08 on Accern's scale. They also gave media stories about the medical device company an impact score of 45.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are NuVasive's major shareholders?
NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Champlain Investment Partners LLC (6.13%), Fisher Asset Management LLC (2.49%), Dimensional Fund Advisors LP (2.31%), Eagle Asset Management Inc. (2.19%), OppenheimerFunds Inc. (1.72%) and Northern Trust Corp (1.53%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.
Which institutional investors are selling NuVasive stock?
NUVA stock was sold by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, OppenheimerFunds Inc., Scout Investments Inc., PNC Financial Services Group Inc., Eos Focused Equity Management L.P., Stevens Capital Management LP, Fisher Asset Management LLC and Eagle Asset Management Inc.. View Insider Buying and Selling for NuVasive.
Which institutional investors are buying NuVasive stock?
NUVA stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Rock Springs Capital Management LP, Victory Capital Management Inc., Champlain Investment Partners LLC, Hood River Capital Management LLC, Mesirow Financial Investment Management Equity Management, Dimensional Fund Advisors LP and Fort Washington Investment Advisors Inc. OH. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $52.31.
How big of a company is NuVasive?
NuVasive has a market capitalization of $2.76 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
